On August 4, 2022, the mpox outbreak
was declared a public health emergency (PHE) in the United States.
From the outset, HRSA engaged with federal partners across HHS to
provide resources to combat the spread of mpox; assist health care
providers who are treating people who have mpox; and ensure those
who are most at risk are the focus of vaccine response efforts. HHS
authorized HRSA to receive allotments of the JYNNEOS vaccine for
mpox for rapid distribution to Ryan White HIV/AIDS Program (RWHAP)
recipients. HRSA was identified as a distribution partner due to
the health care services provided to individuals with HIV and the
number of uninsured and underinsured persons seen in RWHAP and
Health Center Programs. The allotments were meant to supplement,
not replace, vaccine efforts at jurisdictional levels. To expedite
dispensing of the vaccine, HRSA provided the vaccine to dually
funded RWHAP Part C and Health Center providers that care for
at-risk populations. Most of the identified providers already had
access to the Health Partner Ordering Portal (HPOP), a system HHS
uses to quickly distribute vaccines to HHS health partners. For
providers who elected to receive the vaccine but did not have
access to HPOP, HRSA registered them in the HPOP system. HRSA made
73 shipments to 57 (53 dually funded and four Part C only) RWHAP
recipients who elected to receive and distribute the mpox vaccine.
RWHAP recipients that receive shipments of the JYNNEOS vaccine are
required to upload administration and inventory/wastage data into
HPOP on a weekly basis. The information collected includes federal
or state PIN, contact, lot number, description, number of vials,
expiration date, courses/doses/bottles administered, bottles
available, wastage, reason, and date reported. RWHAP recipients who
accept JYNNEOS vaccine from HRSA are also asked to submit data with
information necessary for HRSA to assess the quantity of mpox
vaccines requested and their distribution status. The information
collected includes grant number; recipient name, point of contact,
and phone number; shipping address; shipping point of contact,
email address, and phone number; and number of boxes of mpox
vaccine requested. As a result of the PHE for mpox, the Assistant
Secretary for Planning and Evaluation issued a Paperwork Reduction
Act waiver for collection of these data. Since the PHE ended on
January 31, 2023, HRSA is proposing to continue collecting these
data until December 31, 2025. This action will help to improve
HRSA’s ability to provide additional resources and assistance to
RWHAP recipients, which may result in increased prevention of mpox
among RWHAP clients.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.